文献速递肝胆胰外科围术期管理与 ERAS

射频消融与微创肝切除治疗小肝癌的系统评价与Meta分析

Efficacy and safety of radiofrequency ablation versus minimally invasive liver surgery for small hepatocellular carcinoma: a systematic review and meta-analysis.
PubMed 文献 · Surg Endosc · 2019-04-11

该系统评价与Meta分析纳入6项回顾性研究共597例小肝癌患者,比较射频消融(RFA,313例)与微创肝手术(MIS,284例)。MIS组3年总生存率和无病生存率均优于RFA,局部肝内复发率更低;RFA组术后并发症更少、手术时间和住院时间更短。RFA可作为单发≤3 cm小肝癌的替代治疗选择,但证据等级较低。

要点

  • MIS组3年总生存率和无病生存率优于RFA,局部复发率更低
  • RFA组并发症更少、手术时间和住院时间更短
  • RFA可作为单发≤3 cm小肝癌的替代治疗,但证据等级低

核心结论

  • MIS在小肝癌患者中带来更高的总生存率、无病生存率和更低的局部复发率。
  • RFA治疗并发症率更低、手术时间和住院时间更短。
  • 考虑长期结局,MIS优于RFA,但RFA可作为单发≤3 cm小肝癌的替代治疗。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase、Cochrane Library、Web of Science和CBM数据库至2018年7月。
  • 纳入6项回顾性研究,共597例患者,其中RFA组313例,MIS组284例。

主要发现

  • MIS组3年总生存率显著高于RFA组(OR 0.55;95% CI 0.36至0.84)。
  • MIS组3年无病生存率也优于RFA组(OR 0.63;95% CI 0.41至0.98)。
  • RFA组局部肝内复发率显著高于MIS组(OR 2.24;95% CI 1.47至3.42)。
  • RFA组术后并发症发生率低于MIS组(OR 0.34;95% CI 0.22至0.53)。
  • RFA组手术时间更短(OR -145.31,95% CI -200.24至-90.38),住院时间更短(OR -4.02,95% CI -4.94至-3.10)。

关键数值与推荐

  • 纳入比较RFA与MIS治疗小肝癌的研究,评估总生存率、无病生存率、局部复发率、并发症率、住院时间和手术时间。

临床怎么用

  • 对于小肝癌患者,MIS在长期生存和局部控制方面优于RFA,应优先考虑。
  • 对于单发≤3 cm小肝癌,RFA可作为微创替代治疗选择,尤其适合关注并发症和恢复速度的患者。

局限性

  • 纳入研究均为回顾性研究,证据等级较低。
  • 研究结论需谨慎解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to compare radiofrequency ablation (RFA) with minimally invasive liver surgery (MIS) in the treatment of small hepatocellular carcinoma (SHCC) and to assess short-term and long-term clinical outcomes. METHODS: PubMed, Embase, Cochrane Library, Web of science, and CBM were systematically searched for articles from inception to July 2018, comparing RFA and MIS in SHCC treatment. We evaluated overall survival (OS), disease-free survival (DFS), local recurrence, and complication rates, as well as hospitalization duration and operation times. RESULTS: Six retrospective studies were analyzed, including a total of 597 patients, 313 treated with RFA and 284 treated with MIS. OS rates were significantly higher in patients treated with MIS at 3 years, when compared to RFA (OR 0.55; 95% CI 0.36 to 0.84). The 3-year DFS MIS rates were also superior to RFA (OR 0.63; 95% CI 0.41 to 0.98). In contrast, when compared to MIS, RFA demonstrated a significantly higher rate of local intrahepatic recurrences, (OR 2.24; 95% CI 1.47 to 3.42), and a lower incidence of postoperative complications (OR 0.34; 95% CI 0.22 to 0.53), as well as shorter operation times (OR - 145.31, 95% CI - 200.24 to - 90.38) and hospitalization duration (OR - 4.02,95% CI - 4.94 to - 3.10). CONCLUSIONS: We found that MIS led to higher OS, DFS, and lower local recurrences in SHCC patients. Meanwhile, RFA treatments led to significantly lower complication rates, shorter operation times, and hospitalization duration. Considering long-term outcomes, MIS was found to be superior to RFA. However, RFA may be an alternative treatment for patients presenting a single SHCC nodule (≤ 3 cm), given its minimally invasive nature and its comparable long-term efficacy with MIS. Nevertheless, our findings should be explained with caution due to the low level of evidence obtained.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Si MB, Yan PJ, Hao XY, et al. Efficacy and safety of radiofrequency ablation versus minimally invasive liver surgery for small hepatocellular carcinoma: a systematic review and meta-analysis. Surg Endosc. 2019. PMID: 30989373. doi:10.1007/s00464-019-06784-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。